BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26161698)

  • 21. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP; Tjahjono DH
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Bose P; Simmons GL; Grant S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
    Goel B; Tripathi N; Bhardwaj N; Jain SK
    Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in CDK inhibitors for cancer therapy.
    Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
    Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
    Balakrishnan A; Vyas A; Deshpande K; Vyas D
    World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
    Bruyère C; Meijer L
    Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
    Basso AD; Doll RJ
    Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):357-67. PubMed ID: 18221046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
    Qin A; Reddy HG; Weinberg FD; Kalemkerian GP
    Expert Opin Pharmacother; 2020 Jun; 21(8):941-952. PubMed ID: 32164461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The history and future of targeting cyclin-dependent kinases in cancer therapy.
    Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
    Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
    Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
    J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
    Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
    Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer therapeutic strategies based on CDK inhibitors.
    Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
    Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
    Liang H; Du J; Elhassan RM; Hou X; Fang H
    Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
    [No Abstract]   [Full Text] [Related]  

  • 39. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
    Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
    Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.